SCHEMBL13657254

SCHEMBL13657254

CCOC(=O)C(Cc1ccccc1)NP(=O)(Cl)Oc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPRT1 P00492 1/20 0.55
MMP8 P22894 1/20 0.47
GAA P10253 1/20 0.46
RAB9A P51151 1/20 0.46
BTN3A1 O00481 4/20 0.45
ELANE P08246 1/20 0.44
F2 P00734 1/20 0.43
PLG P00747 1/20 0.43
PLAU P00749 1/20 0.43
PLAT P00750 1/20 0.43
TP53 P04637 1/20 0.43
PTGS2 P35354 1/20 0.43
PPARG P37231 2/20 0.43
ANPEP P15144 1/20 0.43
LAP3 P28838 1/20 0.43
EPHX2 P34913 1/20 0.43
TACR1 P25103 1/20 0.42
LMNA P02545 1/20 0.42
PPARA Q07869 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13875634 1.00 HPRT1 (0.55) HPRT1MMP8GAARAB9ABTN3A1
SCHEMBL25528564 0.90 HPRT1 (0.47) HPRT1GAARAB9AELANEF2
SCHEMBL12621364 0.90 ATM (0.50) GAARAB9AANPEPLMNA
SCHEMBL25541493 0.90 HPRT1 (0.45) HPRT1MMP8GAARAB9ABTN3A1
SCHEMBL12467482 0.88 HPRT1 (0.46) HPRT1GAARAB9AANPEPLAP3
SCHEMBL25526042 0.87 HPRT1 (0.45) HPRT1GAARAB9ALMNA
SCHEMBL25526186 0.86 HPRT1 (0.44) HPRT1RAB9ALMNA
SCHEMBL25526187 0.86 HPRT1 (0.44) HPRT1RAB9ALMNA
SCHEMBL25526195 0.86 HPRT1 (0.44) HPRT1RAB9ALMNA
SCHEMBL30335207 0.86 HPRT1 (0.44) HPRT1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107148423-B Thionucleoside derivative or salt thereof and pharmaceutical composition 富士胶片株式会社 2021-07-30 CN disclosed
WO-2019118486-A1 MONOSACCHARIDE PHOSPHORAMIDATE PRODRUGS CERECOR INC. (US) 2019-06-20 WO disclosed
US-7608599-B2 Antiviral phosphoramidates ROCHE PALO ALTO LLC (US) 2009-10-27 US disclosed
US-20070042988-A1 Antiviral phosphoramidates ROCHE PALO ALTO LLC 2007-02-22 US disclosed
US-20070042988-A1 Antiviral phosphoramidates ROCHE PALO ALTO LLC 2007-02-22 US disclosed
WO-2007020193-A2 ANTIVIRAL PHOSPHORAMIDATES OF 4 ' -SUBSTITUTED PRONUCLEOTIDES F. HOFFMANN-LA ROCHE AG (CH) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070042988-A1 Antiviral phosphoramidates RPP30, RNASE1, ADORA2B HPRT1 105/4885MMP8 4404/4885GAA 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.